STOCKSHOTS of Merck's campus in Rahway, New Jersey as the American pharmaceutical group, known as MSD outside of North America, announces it will acquire the British biotech Verona Pharma for approximately $10 billion. This transaction, which is expected to be completed in the fourth quarter of 2025, will allow Merck to get its hands on Ohtuvayre, a treatment for chronic obstructive pulmonary disease (or COPD), a chronic inflammatory bronchial disease, and thereby expand its portfolio of drugs in cardiopulmonary diseases. STOCKSHOTS